For example, a study published by Göğebakan and Çetin demonstrated that certolizumab treatment reduced the risk of cardiovascular events in patients with ankylosing spondylitis by increasing insulin sensitivity and improving lipid components such as high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) (Göğebakan and Yıldırım Çetin 2022). This evidence concerns the gene INS and ankylosing spondylitis.